



Monday, 29 June 2009

## **PRESS RELEASE**

### **“Help for lymphoedema sufferers” Independent lymphoedema article publishes in the Weekend Australian Newspaper on the benefits of early detection**

ImpediMed Limited would like to bring to the attention of all shareholders an article published in the Health section of last week-end's Australian Newspaper, titled “Help for lymphoedema sufferers”. “Detection may mean prevention for this common and debilitating side effect of cancer therapy”

<http://www.theaustralian.news.com.au/story/0,25197,25690834-23289,00.html>

“It is very encouraging to see an independent article publish on the benefits of early detection in preventing lymphedema progression in cancer patients. The article clearly demonstrates what a prevalent issue lymphoedema is here in Australia. It also highlights the significant impact this disorder can have on both the quality of life for a survivor and the ongoing costs of care to the healthcare system and the patient, commented Greg Brown, CEO of ImpediMed.

The additional costs lymphoedema creates for the US healthcare system were well described in the Journal of Clinical Oncology article from March this year, summarised in an ASX release on 19<sup>th</sup> March 2009. In this publication it was shown that the additional costs for lymphoedema in breast cancer patients ranged from US\$14,877 to US\$23,167 over the two year study period alone. The article also concluded that the study likely underestimated the costs of breast cancer related lymphoedema.

Mr Brown went on to say “A pre-emptive care treatment regime for lymphoedema in all breast cancer patients has enormous potential to generate savings for the healthcare system, while improving the quality of life for survivors. It is deeply satisfying to see such globally respected Australian professionals, referenced in the Australian article, discussing the potential benefits of early detection. This demonstrates just how proactive the Australian healthcare system is in considering the best options of care for patients.”

ImpediMed is the only supplier globally of bio-impedance spectroscopy (BIS) devices and has the first FDA cleared device for aiding in the clinical assessment of lymphoedema”

**ENDS**

For personal use only

**For further information contact:**

**Greg Brown**

**Impedimed CEO**

**+61-7-3860-3700**

L-Dex™ is a trademark of ImpediMed Limited

**About ImpediMed**

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients. For more information, visit. [www.impedimed.com](http://www.impedimed.com).

For personal use only